動物用鎮静剤市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、投与経路別、地域別、競合別、2020～2030年

動物用鎮静剤の世界市場規模は2024年に1億3,204万米ドル、予測期間中のCAGRは4.65%で2030年には1億7,386万米ドルに達すると予測されています。

動物用鎮静剤市場は、COVID-19パンデミックの初期段階で顕著な混乱が見られました。これは主に、世界各国の政府が封鎖や社会的距離を置くといった封じ込め策を大々的に実施したためで、動物病院や薬局の業務が大幅に縮小しました。例えば、Faunalyticsが2022年12月に実施した調査によると、パンデミック時に病気の伝番を防ぐため、米国とカナダでは約70％のクリニックが一般診療を一時的に停止し、動物が飼い主や保護者なしで予約診療を受けなければならない状況に陥ったことが明らかになりました。

市場促進要因

ペット飼育数の増加

主要市場課題

倫理的懸念

主要市場動向

鎮静剤配合の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の動物用鎮静剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（アセプロマジン、ブトルファノール、デトミジン、ロミフィジン、キシラジン）
  • 投与経路別（経口、非経口）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米の動物用鎮静剤市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の動物用鎮静剤市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋の動物用鎮静剤市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の動物用鎮静剤市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの動物用鎮静剤市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（該当する場合）
• 製品の発売（該当する場合）

第13章 ポーターのファイブフォース分析

• 産業内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Zoetis Inc
• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.
• Elanco Animal Health Inc
• Virbac S.A.
• Dechra Pharmaceuticals Limited
• Orion Corporation
• Vetoquinol SA
• Bimeda, Inc.
• Chanelle Pharma Group

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Animal Sedative Market was valued at USD 132.04 Million in 2024 and is expected to reach USD 173.86 Million by 2030 with a CAGR of 4.65% during the forecast period. The animal sedative market saw a notable disruption during the initial phase of the COVID-19 pandemic. This was primarily due to the extensive implementation of containment measures like lockdowns and social distancing by governments worldwide, which significantly reduced the operations of veterinary hospitals and pharmacies. For instance, a study conducted by Faunalytics in December 2022 revealed that in order to prevent disease transmission during the pandemic, approximately 70% of clinics in the United States and Canada temporarily suspended public access, leading to situations where animals had to attend appointments without their owners or guardians.

Key Market Drivers

Increasing Pet Ownership

Pet ownership has become a global phenomenon, with millions of households worldwide welcoming furry, feathered, or scaly companions into their lives. This surge in pet ownership is not just about companionship; it's also driving growth in various industries, including veterinary care and pharmaceuticals.

As more people open their homes to pets, there is a growing emphasis on pet healthcare. Pet owners are increasingly recognizing the importance of regular veterinary check-ups, vaccinations, and surgical procedures when needed. For these medical interventions, sedation is often required to ensure the safety and comfort of the animals. In May 2023, Virbac acquired GS Partners, its long-term distributor in the Czech Republic and Slovakia, marking its 35th subsidiary and strengthening its position in Central Europe. This acquisition aims to boost Virbac's capacity to address the animal health needs in the region, particularly focusing on the pet and ruminant sectors.

Key Market Challenges

Ethical Concerns

Ethical concerns surrounding animal testing are a growing issue in the veterinary and pharmaceutical industries, raising questions about the morality and necessity of using animals for testing purposes. The use of animals to test the safety and efficacy of new sedatives, vaccines, and other treatments presents a delicate balance between ensuring product effectiveness and minimizing harm to animals. As consumers and regulatory bodies place increasing importance on animal welfare, companies in the industry are under pressure to adopt more humane practices. Many organizations are prioritizing the reduction of animal testing through the development and implementation of alternative testing methods, such as in vitro models, organ-on-a-chip technologies, and computer simulations. These advancements offer potential solutions to alleviate the ethical burden by providing more reliable, humane alternatives. Nonetheless, it is still an ongoing challenge to ensure that these alternatives meet the rigorous standards required for veterinary treatments while still maintaining the highest level of animal welfare possible.

Key Market Trends

Advancements in Sedative Formulations

Recent innovations in pharmaceutical research have led to the development of more effective, safer, and faster-acting sedatives for veterinary use. These advancements are revolutionizing the way sedation is administered in animals, improving the quality of care and reducing the risks associated with traditional sedatives. New formulations are designed to not only act more quickly but also to minimize side effects, such as post-sedation confusion or extended recovery times, which can sometimes occur with older sedative agents. These newer sedatives often provide better control over the depth and duration of sedation, allowing veterinarians to perform procedures with greater precision and confidence. In November 2022, SeQuent Scientific Limited (SeQuent), a prominent Indian company specializing in animal health products, particularly veterinary formulations and APIs, entered into a binding agreement to purchase the entire ownership stake, equivalent to 100%, in Tineta Pharma Private Limited (Tineta), an Indian-based company.

Additionally, many of these advanced formulations are designed with a lower risk of adverse reactions, reducing the likelihood of complications during or after the procedure. This ensures a safer overall experience for the animal, leading to quicker recovery times and less stress on both the animal and the veterinary team. The continued research and development in sedative formulations are making veterinary procedures more efficient, safer, and more comfortable for animals, improving both clinical outcomes and the overall experience for veterinary professionals.

Key Market Players

• Zoetis Inc
• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.
• Elanco Animal Health Inc
• Virbac S.A.
• Dechra Pharmaceuticals Limited
• Orion Corporation
• Vetoquinol SA
• Bimeda, Inc.
• Chanelle Pharma Group

Report Scope:

In this report, the Global Animal Sedative Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Sedative Market, By Type:

• Acepromazine
• Butorphanol
• Detomidine
• Romifidine
• Xylazine

Animal Sedative Market, By Route of Administration:

• Oral
• Parenteral

Animal Sedative Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Sedative Market.

Available Customizations:

Global Animal Sedative market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Animal Sedative Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Acepromazine, Butorphanol, Detomidine, Romifidine, Xylazine)
  • 5.2.2. By Route of Administration (Oral, Parenteral)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Animal Sedative Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Route Of Administration
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Animal Sedative Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Route Of Administration
  • 6.3.2. Canada Animal Sedative Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Route Of Administration
  • 6.3.3. Mexico Animal Sedative Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Route Of Administration

7. Europe Animal Sedative Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Route Of Administration
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Animal Sedative Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Route Of Administration
  • 7.3.2. United Kingdom Animal Sedative Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Route Of Administration
  • 7.3.3. Italy Animal Sedative Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Route Of Administration
  • 7.3.4. France Animal Sedative Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Route Of Administration
  • 7.3.5. Spain Animal Sedative Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Route Of Administration

8. Asia-Pacific Animal Sedative Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Route Of Administration
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Animal Sedative Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Route Of Administration
  • 8.3.2. India Animal Sedative Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Route Of Administration
  • 8.3.3. Japan Animal Sedative Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Route Of Administration
  • 8.3.4. South Korea Animal Sedative Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Route Of Administration
  • 8.3.5. Australia Animal Sedative Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Route Of Administration

9. South America Animal Sedative Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Route Of Administration
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Animal Sedative Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Route Of Administration
  • 9.3.2. Argentina Animal Sedative Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Route Of Administration
  • 9.3.3. Colombia Animal Sedative Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Route Of Administration

10. Middle East and Africa Animal Sedative Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Route Of Administration
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Animal Sedative Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Route Of Administration
  • 10.3.2. Saudi Arabia Animal Sedative Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Route Of Administration
  • 10.3.3. UAE Animal Sedative Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Route Of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Zoetis Inc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Boehringer Ingelheim International GmbH
• 14.3. Merck & Co., Inc.
• 14.4. Elanco Animal Health Inc
• 14.5. Virbac S.A.
• 14.6. Dechra Pharmaceuticals Limited
• 14.7. Orion Corporation
• 14.8. Vetoquinol SA
• 14.9. Bimeda, Inc.
• 14.10. Chanelle Pharma Group

15. Strategic Recommendations

16. About Us & Disclaimer